Need help finding what you are looking for?
Contact Us
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2020214
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2020214
Antipsychotic Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
PUBLISHED:
PAGES: 195 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Growth Factors of antipsychotic drugs Market
The global antipsychotic drugs market was valued at USD 18.51 billion in 2025 and is projected to grow to USD 19.71 billion in 2026, ultimately reaching USD 27.48 billion by 2034, exhibiting a CAGR of 5.24% during the forecast period. North America dominated the global market in 2025 with a share of 52.32%, driven by the high prevalence of psychiatric illnesses, strong presence of leading biopharmaceutical companies, and the adoption of technologically advanced antipsychotic medications.
Market Overview
Psychiatric illnesses, including schizophrenia, bipolar disorder, and depression, are the primary drivers of the antipsychotic drugs market. Psychosis, a key symptom of these illnesses, affects patients' perception of reality and information processing. The rising prevalence of schizophrenia and bipolar disorder has fueled the demand for effective antipsychotic medications globally. Moreover, the adoption of newer drug formulations, particularly long-acting injectables (LAIs), has significantly enhanced treatment adherence and outcomes.
COVID-19 also influenced the market positively by accelerating the transition toward telemedicine for psychiatric care, which increased medication adoption. Market growth is expected to stabilize between 2024 and 2032 due to improved healthcare systems and treatment accessibility.
Market Segmentation
By Disease:
- Schizophrenia: The fastest-growing segment due to its global prevalence and the launch of multiple innovative products.
- Bipolar Disorder: Second-largest segment, with drugs helping stabilize symptoms. Lifetime prevalence is around 1%, with a one-year prevalence of 0.5%.
- Unipolar Depression: Third-largest segment, with medications like Rexulti providing symptomatic relief.
- Dementia: Smaller segment due to the FDA black box warning limiting antipsychotic use in elderly patients.
By Therapeutic Class:
- Second Generation Antipsychotics dominated with a 76.12% share in 2026, thanks to a superior safety profile and drugs like SEROQUEL XR, ZYPREXA, VRAYLAR, INVEGA HAFYERA, and Rexulti.
- Third Generation is expected to exhibit the highest CAGR, supported by new product launches and technological advancements.
- First Generation shows the lowest growth due to higher risk of neurological side effects.
By Drug:
- Aripiprazole leads in growth due to third-generation adoption and significant product approvals, including the FDA-approved 2-month LAI for schizophrenia and bipolar I disorder (2022).
- Paliperidone Palmitate holds the second-largest market share, with INVEGA HAFYERA being the first twice-yearly injectable approved for schizophrenia in adults (2021).
- Other drugs contribute to market dominance due to the variety of available options.
By Distribution Channel:
- Hospital pharmacies account for the largest market share (43.54% in 2026) as most antipsychotics require prescription and monitoring.
- Online pharmacies are expected to grow the fastest due to patient convenience.
- Drug stores & retail pharmacies remain significant for prescription refills and oral medications.
Regional Insights
- North America: Market size USD 9.69 billion in 2025, projected USD 10.33 billion in 2026, dominating due to prevalence, R&D, and technological adoption.
- Europe: USD 3.91 billion in 2025, USD 4.13 billion in 2026; strong government spending and awareness boost market growth.
- Asia Pacific: USD 3.73 billion in 2025, USD 4.03 billion in 2026; fastest-growing region due to emerging countries like China and India.
- Latin America: USD 0.74 billion in 2025, USD 0.77 billion in 2026; growth driven by increased awareness and healthcare expenditure.
- Middle East & Africa: USD 0.45 billion in 2025, USD 0.46 billion in 2026; limited share but growing due to improved healthcare systems.
Market Trends and Growth Drivers
1. Adoption of Long-Acting Injectables (LAIs): LAIs improve adherence and reduce relapse risks. For example, Paliperidone LAIs require administration only four times a year.
2. R&D Initiatives: Companies like Karuna Therapeutics are developing innovative drugs like KarXT for schizophrenia and psychosis in Alzheimer's.
3. Rising Prevalence of Mental Disorders: WHO predicts mental disorders will cost the global economy USD 6 trillion by 2030, intensifying demand.
Restraining Factors
Adverse effects, including weight gain, sedation, digestive issues, and tardive dyskinesia, can lead to non-adherence. Black box warnings, such as for dementia patients, also limit market adoption.
Key Players
- Janssen Global Services LLC - Invega Sustenna, Risperdal Consta
- Otsuka Pharmaceutical Co., Ltd. - Abilify Maintena, Rexulti
- Eli Lilly and Company - Various antipsychotics
- Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Bristol-Myers Squibb, Dr. Reddy's Laboratories, Sumitomo Dainippon Pharma Co., Alkermes plc
Industry Developments
- January 2024: Teva completes Phase 3 trial for once-monthly olanzapine LAI.
- April 2023: FDA approves UZEDY (risperidone LAI) by Teva and MedinCell.
- January 2022: FDA approves REXULTI for adolescents (13-17 years) with schizophrenia.
Conclusion
The global antipsychotic drugs market is poised for steady growth from 2025 to 2034, driven by rising mental health disorders, innovative LAIs, and active R&D pipelines. North America will continue to lead, while Asia Pacific emerges as the fastest-growing market, supported by awareness programs and increasing patient adoption of modern therapies.
Segmentation By Disease
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
By Drug
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Brexpiprazole
- Paliperidone Palmitate
- Others
By Therapeutic Class
- First Generation
- Second Generation
- Third Generation
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Region
- North America (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country)
- U.S. (By Disease)
- Canada (By Disease)
- Europe (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
- Germany (By Disease)
- U.K. (By Disease)
- France (By Disease)
- Italy (By Disease)
- Spain (By Disease)
- Scandinavia (By Disease)
- Rest of Europe (By Disease)
- Asia Pacific (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
- China (By Disease)
- Japan (By Disease)
- India (By Disease)
- Australia (By Disease)
- Southeast Asia (By Disease)
- Rest of Asia Pacific (By Disease)
- Latin America (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
- Brazil (By Disease)
- Mexico (By Disease)
- Rest of Latin America (By Disease)
- Middle East & Africa (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
- GCC (By Disease)
- South Africa (By Disease)
- Rest of Middle East & Africa (By Disease)
Product Code: FBI101390
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Psychiatric Disorders, By Key Countries/Regions
- 4.2. Analysis of the Cost and Burden of Mental Health Disorders
- 4.3. Overview of Current Advances in R&D for Antipsychotic Drugs
- 4.4. Pipeline Analysis, Key Players
- 4.5. Analysis: First Generation Antipsychotics vs. Third Generation Antipsychotics
- 4.6. Key Industry Developments, Mergers, Acquisitions, Etc.
- 4.7. New Product Launches
- 4.8. Impact of COVID-19 on Antipsychotic Drugs Market
5. Global Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast- By Disease
- 5.1.1. Schizophrenia
- 5.1.2. Bipolar Disorder
- 5.1.3. Unipolar Depression
- 5.1.4. Dementia
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast- By Drug
- 5.2.1. Risperidone
- 5.2.2. Quetiapine
- 5.2.3. Olanzapine
- 5.2.4. Aripiprazole
- 5.2.5. Brexpiprazole
- 5.2.6. Paliperidone Palmitate
- 5.2.7. Others
- 5.3. Market Analysis, Insights and Forecast - By Therapeutic Class
- 5.3.1. First Generation
- 5.3.2. Second Generation
- 5.3.3. Third Generation
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Drug Stores & Retail Pharmacies
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast- By Disease
- 6.1.1. Schizophrenia
- 6.1.2. Bipolar Disorder
- 6.1.3. Unipolar Depression
- 6.1.4. Dementia
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast- By Drug
- 6.2.1. Risperidone
- 6.2.2. Quetiapine
- 6.2.3. Olanzapine
- 6.2.4. Aripiprazole
- 6.2.5. Brexpiprazole
- 6.2.6. Paliperidone Palmitate
- 6.2.7. Others
- 6.3. Market Analysis, Insights and Forecast - By Therapeutic Class
- 6.3.1. First Generation
- 6.3.2. Second Generation
- 6.3.3. Third Generation
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Drug Stores & Retail Pharmacies
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.1.1. By Disease
- 6.5.2. Canada
- 6.5.2.1. By Disease
- 6.5.1. U.S.
7. Europe Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast- By Disease
- 7.1.1. Schizophrenia
- 7.1.2. Bipolar Disorder
- 7.1.3. Unipolar Depression
- 7.1.4. Dementia
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast- By Drug
- 7.2.1. Risperidone
- 7.2.2. Quetiapine
- 7.2.3. Olanzapine
- 7.2.4. Aripiprazole
- 7.2.5. Brexpiprazole
- 7.2.6. Paliperidone Palmitate
- 7.2.7. Others
- 7.3. Market Analysis, Insights and Forecast - By Therapeutic Class
- 7.3.1. First Generation
- 7.3.2. Second Generation
- 7.3.3. Third Generation
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Drug Stores & Retail Pharmacies
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. Germany
- 7.5.1.1. By Disease
- 7.5.2. U.K.
- 7.5.2.1. By Disease
- 7.5.3. France
- 7.5.3.1. By Disease
- 7.5.4. Italy
- 7.5.4.1. By Disease
- 7.5.5. Spain
- 7.5.5.1. By Disease
- 7.5.6. Scandinavia
- 7.5.6.1. By Disease
- 7.5.7. Rest of Europe
- 7.5.7.1. By Disease
- 7.5.1. Germany
8. Asia Pacific Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast- By Disease
- 8.1.1. Schizophrenia
- 8.1.2. Bipolar Disorder
- 8.1.3. Unipolar Depression
- 8.1.4. Dementia
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast- By Drug
- 8.2.1. Risperidone
- 8.2.2. Quetiapine
- 8.2.3. Olanzapine
- 8.2.4. Aripiprazole
- 8.2.5. Brexpiprazole
- 8.2.6. Paliperidone Palmitate
- 8.2.7. Others
- 8.3. Market Analysis, Insights and Forecast - By Therapeutic Class
- 8.3.1. First Generation
- 8.3.2. Second Generation
- 8.3.3. Third Generation
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Drug Stores & Retail Pharmacies
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.1.1. By Disease
- 8.5.2. India
- 8.5.2.1. By Disease
- 8.5.3. Japan
- 8.5.3.1. By Disease
- 8.5.4. Australia
- 8.5.4.1. By Disease
- 8.5.5. Southeast Asia
- 8.5.5.1. By Disease
- 8.5.6. Rest of Asia Pacific
- 8.5.6.1. By Disease
- 8.5.1. China
9. Latin America Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast- By Disease
- 9.1.1. Schizophrenia
- 9.1.2. Bipolar Disorder
- 9.1.3. Unipolar Depression
- 9.1.4. Dementia
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast- By Drug
- 9.2.1. Risperidone
- 9.2.2. Quetiapine
- 9.2.3. Olanzapine
- 9.2.4. Aripiprazole
- 9.2.5. Brexpiprazole
- 9.2.6. Paliperidone Palmitate
- 9.2.7. Others
- 9.3. Market Analysis, Insights and Forecast - By Therapeutic Class
- 9.3.1. First Generation
- 9.3.2. Second Generation
- 9.3.3. Third Generation
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Drug Stores & Retail Pharmacies
- 9.4.3. Online Pharmacies
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.1.1. By Disease
- 9.5.2. Mexico
- 9.5.2.1. By Disease
- 9.5.3. Rest of Latin America
- 9.5.3.1. By Disease
- 9.5.1. Brazil
10. Middle East & Africa Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast- By Disease
- 10.1.1. Schizophrenia
- 10.1.2. Bipolar Disorder
- 10.1.3. Unipolar Depression
- 10.1.4. Dementia
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast- By Drug
- 10.2.1. Risperidone
- 10.2.2. Quetiapine
- 10.2.3. Olanzapine
- 10.2.4. Aripiprazole
- 10.2.5. Brexpiprazole
- 10.2.6. Paliperidone Palmitate
- 10.2.7. Others
- 10.3. Market Analysis, Insights and Forecast - By Therapeutic Class
- 10.3.1. First Generation
- 10.3.2. Second Generation
- 10.3.3. Third Generation
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Drug Stores & Retail Pharmacies
- 10.4.3. Online Pharmacies
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.1.1. By Disease
- 10.5.2. South Africa
- 10.5.2.1. By Disease
- 10.5.3. Rest of Middle East & Africa
- 10.5.3.1. By Disease
- 10.5.1. GCC
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2026)
- 11.2. Company Profiles
- 11.2.1. Otsuka Pharmaceutical Co., Ltd.
- 11.2.1.1. Overview
- 11.2.1.2. Products & Services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- 11.2.2.1. Overview
- 11.2.2.2. Products & Services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Teva Pharmaceutical Industries Ltd.
- 11.2.3.1. Overview
- 11.2.3.2. Products & Services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Dr. Reddy's Laboratories Ltd.
- 11.2.4.1. Overview
- 11.2.4.2. Products & Services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. H. Lundbeck A/S
- 11.2.5.1. Overview
- 11.2.5.2. Products & Services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. ALLERGAN (AbbVie, Inc.)
- 11.2.6.1. Overview
- 11.2.6.2. Products & Services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Eli Lilly and Company
- 11.2.7.1. Overview
- 11.2.7.2. Products & Services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Alkermes plc
- 11.2.8.1. Overview
- 11.2.8.2. Products & Services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Bristol-Myers Squibb Company
- 11.2.9.1. Overview
- 11.2.9.2. Products & Services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Sumitomo Dainippon Pharma Co., Ltd.
- 11.2.10.1. Overview
- 11.2.10.2. Products & Services
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.1. Otsuka Pharmaceutical Co., Ltd.
Product Code: FBI101390
List of Tables
- Table 01: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 02: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
- Table 03: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
- Table 04: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 05: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Region, 2021-2034
- Table 06: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 07: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
- Table 08: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
- Table 09: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 10: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 11: U.S. Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 12: Canada Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 13: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 14: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
- Table 15: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
- Table 16: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 17: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 18: Germany Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 19: U.K. Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 20: France Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 21: Italy Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 22: Spain Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 23: Scandinavia Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 24: Rest of Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 25: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 26: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
- Table 27: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
- Table 28: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 29: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 30: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 31: China Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 32: India Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 33: Japan Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 34: Australia Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 35: South East Asia Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 36: Rest of Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 37: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 38: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
- Table 39: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
- Table 40: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 41: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 42: Brazil Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 43: Mexico Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 44: Rest of Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 45: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 46: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
- Table 47: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
- Table 48: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 49: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 50: South Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 51: GCC Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
- Table 52: Rest of Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
List of Figures
- Figure 01: Global Antipsychotic Drugs Market Value Share (%), By Disease, 2026 & 2034
- Figure 02: Global Antipsychotic Drugs Market Value Share (%), By Drug, 2026 & 2034
- Figure 03: Global Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026 & 2034
- Figure 04: Global Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026 & 2034
- Figure 05: Global Antipsychotic Drugs Market Value Share (%), By Region, 2026 & 2034
- Figure 06: North America Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
- Figure 07: North America Antipsychotic Drugs Market Value Share (%), By Disease, 2026
- Figure 08: North America Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
- Figure 09: North America Antipsychotic Drugs Market Value Share (%), By Drug, 2026
- Figure 10: North America Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
- Figure 11: North America Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
- Figure 12: North America Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
- Figure 13: North America Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
- Figure 14: North America Antipsychotic Drugs Market Value (USD billion), By Country, 2026 & 2034
- Figure 15: North America Antipsychotic Drugs Market Value Share (%), By Country, 2026
- Figure 16: Europe Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
- Figure 17: Europe Antipsychotic Drugs Market Value Share (%), By Disease, 2026
- Figure 18: Europe Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
- Figure 19: Europe Antipsychotic Drugs Market Value Share (%), By Drug, 2026
- Figure 20: Europe Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
- Figure 21: Europe Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
- Figure 22: Europe Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
- Figure 23: Europe Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026 & 2034
- Figure 24: Europe Antipsychotic Drugs Market Value (USD billion), By Country/Sub-region, 2026 & 2034
- Figure 25: Europe Antipsychotic Drugs Market Value Share (%), By Country/Sub-region, 2026
- Figure 26: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
- Figure 27: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Disease, 2026
- Figure 28: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
- Figure 29: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Drug, 2026
- Figure 30: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
- Figure 31: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
- Figure 32: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
- Figure 33: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
- Figure 34: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
- Figure 35: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Country/ Sub-region, 2026
- Figure 36: Latin America Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
- Figure 37: Latin America Antipsychotic Drugs Market Value Share (%), By Disease, 2026
- Figure 38: Latin America Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
- Figure 39: Latin America Antipsychotic Drugs Market Value Share (%), By Drug, 2026
- Figure 40: Latin America Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
- Figure 41: Latin America Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
- Figure 42: Latin America Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
- Figure 43: Latin America Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
- Figure 44: Latin America Antipsychotic Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
- Figure 45: Latin America Antipsychotic Drugs Market Value Share (%), By Country/ Sub-region, 2026
- Figure 46: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
- Figure 47: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Disease, 2026
- Figure 48: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
- Figure 49: Middle East & Africa Antipsychotic Drugs Market Value Share (%),
- Figure 50: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
- Figure 51: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
- Figure 52: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Distribution Channel 2026 & 2034
- Figure 53: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
- Figure 54: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
- Figure 55: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Country/ Sub-region, 2026
- Figure 56: Global Antipsychotic Drugs Market Share Analysis, By Company, 2026
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.